What is NEUP's P/E ratio?

Neuphoria Therapeutics Inc (NEUP) currently trades at a P/E ratio of 11.28.

Neuphoria Therapeutics Inc reports a Return on Equity (ROE) of -96.80%.

What is NEUP's dividend yield?

Neuphoria Therapeutics Inc offers a dividend yield of 0.00%.

What is NEUP's Quality Score?

Our AI rates NEUP's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NEUP?

Our AI Timing Score for NEUP is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does NEUP belong to?

Neuphoria Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Neuphoria Therapeutics Inc (NEUP) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

NEUP AI Analysis Summary

Our AI summary for NEUP: Neuphoria Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 11.28, ROE of -96.80%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

NEUP

Neuphoria Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 90

USD 3.95

0.06 (1.54%) Day Change

Watchlist Portfolio Compare Chart

11.28

P/E

0.00

D/E

-96.8%

ROE

-81.8%

ROA

0.00%

Div Yield

0.38

PEG

NEUPHORIA THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.95 Price 0.06 (1.54%) Day Change	NEWS SCORE: 90

NEUP, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

51%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	90
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.95
PBV / Sector	0.71 / 44,105.10 GREAT
Earning Per Share	-5.35

PE / Sector	11.28 / 19.37 GOOD
PEG or PE/Growth / Sector	0.38 / 1.06 GOOD
Average 1M Daily Value	1.75 M GREAT
Average 1W Daily Value	0.19 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	271.97 / 97.23 GREAT
NPM Average (%) / Sector	-1,905.77 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-81.82 / 185,260.64
ROA Average (%) / Sector	-67.95 / 36,684.64
ROA Change Average (%) / Sector	2,430.92 / 422,221.42 GOOD
ROE (%) / Sector	-96.80 / 243,761.81
ROE Average (%) / Sector	-89.32 / 48,758.38
ROE Change Average (%) / Sector	1,936.97 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:24
Symbol	NEUP
Name	NEUPHORIA THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	5.40 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	21.02 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 100 Summit Drive, Burlington, MA, United States, 01803

Phone: 781 439 5551

Website: https://www.neuphoriatx.com

Sector: Healthcare >> Biotechnology

Description: Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.